Q32 Bio
CAMBRIDGE · Biotechnology, Healthcare, Health Care
Q32 Bio is a clinical stage biotechnology company whose science targets potent regulators of the adaptive immune system to re-balance immunity and is focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases. Per the National Alopecia Areata Foundation, about 700,000 people in the United States live with alopecia areata, a disease which has a lif
Key facts
- Headquarters
- CAMBRIDGE
- Employees
- 34
- Industries
- Biotechnology, Healthcare, Health Care
- Status
- Public (QTTB)
- Website
- homologymedicines.com
- Company page
Recent activity at Q32 Bio
- : SEC 8-K (7.01): On September 30, 2026, Q32 Bio Inc. issued a press release regarding the results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata. This announcement was made during a late-breaker session at the European Academy of Dermatology and Venereology Congress 2026, highlighting the company's ongoing commitment to advancing dermatological treatments. The information presented is significant as it may influence investor perception of the company's research capabilities and potential market impact. The filing indicates that details of the press release are included as Exhibit 99.1.
- : Q32 Bio Appoints José Trevejo as Chief Medical Officer and Ellie Hershberger as Chief Development Officer
- : SEC 8-K (8.01): On September 14, 2026, Q32 Bio Inc. announced the appointment of José Trevejo, M.D., Ph.D., as the Chief Medical Officer and Ellie Hershberger, Pharm.D., as the Chief Development Officer of the Company. This move is strategic as it reflects the Company's efforts to strengthen its leadership team and advance its developmental goals in the biopharmaceutical sector. The appointments are significant as they bring in experts with extensive backgrounds in medical affairs and drug development, which may enhance the Company's capabilities in bringing new therapies to market.
- : SEC 8-K (1.01): On July 14, 2026, Q32 Bio Inc. entered into a definitive underwriting agreement with Morgan Stanley & Co. LLC, Jefferies LLC, Cantor Fitzgerald & Co., and Oppenheimer & Co. Inc. for a public offering of 6,027,399 shares of common stock at $18.25 per share and pre-funded warrants to purchase up to 4,931,506 shares at $18.2499 each. The offering, which is expected to close on July 16, 2026, aims to raise approximately $187.6 million, with a potential increase to $215.8 million if the underwriters exercise their option for additional shares. The proceeds will support working capital, research, and clinical development, particularly the advancement of the company's asset, bempikibart. Additionally, the warrants allow the holders to purchase shares at a nominal price of $0.0001 each, with specific ownership limitations on exercising the warrants.
- : SEC 8-K (8.01): On July 13, 2026, the Company reported topline results from Part B of the SIGNAL-AA Phase 2a clinical trial evaluating bempikibart (ADX-914) for patients with severe alopecia areata. The trial involved 33 patients with severe AA, with dosing regimens highlighting a significant mean percent reduction in Severity of Alopecia Tool (SALT) scores by 35.3% at 36 weeks. Notably, 40.0% achieved a SALT-20 response, indicating substantial scalp hair coverage. The results showed promising efficacy and safety profiles with no serious adverse events reported, suggesting potential for bempikibart as a treatment option in alopecia areata. This trial builds upon the proof-of-concept established in Part A, indicating continued development of this therapeutic candidate.
- : SEC 8-K (8.01): On July 13, 2026, Q32 Bio Inc. announced topline results from part B of the SIGNAL-AA Phase 2a clinical trial evaluating bempikibart (ADX-914) for alopecia areata. This report includes forward-looking statements regarding the safety, efficacy, and clinical activity of the drug, as well as potential market opportunities for alopecia areata treatments. The filing incorporates a presentation as Exhibit 99.1 detailing the trial outcomes and future expectations. The company cautions that actual results could differ significantly due to associated risks and uncertainties. The event's date directly corresponds to the filing date, making it timely and relevant for investors.
- : SEC 8-K (1.01): On May 26, 2026, Q32 Bio Inc. entered into a Securities Purchase Agreement with accredited investors to sell 6,725,000 shares of common stock at $8.00 per share and pre-funded warrants for an additional 150,000 shares at $7.9999 each, raising approximately $55 million. The agreement includes terms regarding ownership limits for warrant holders and requires the company to file a registration statement within 50 days of the expected closing on May 28, 2026. Morgan Stanley & Co. LLC and Oppenheimer & Co. Inc. are acting as placement agents for the offering, which will support clinical trials and working capital needs.
- : SEC 8-K (8.01):
- : SEC 8-K (1.01): On March 27, 2026, Q32 Bio Inc. entered into a Controlled Equity Offering SM Sales Agreement with Cantor Fitzgerald & Co. for an at-the-market offering program that will allow the Company to offer and sell shares of its common stock. The agreement permits sales of up to $14,200,000 in common stock shares, which will be sold pursuant to the Company's effective shelf registration statement filed on April 11, 2025. The Sales Agent will act under normal trading practices and will receive a 3.0% commission on gross proceeds from any sales. Importantly, the Company can set the parameters for the sales and is not obligated to sell any shares, providing flexibility in the execution of the offering.
- : SEC 8-K (1.01): On February 17, 2026, Q32 Bio Inc. entered into a securities purchase agreement with certain institutional investors for the sale of 1,666,679 shares of its common stock at a price of $3.90 per share, alongside pre-funded warrants for 1,025,654 shares at an offering price of $3.8999 per share. The total gross proceeds from this registered direct offering are expected to be approximately $10.5 million, intended for working capital including clinical development efforts for bempikibart. The offering is scheduled to close on or around February 18, 2026, pending customary closing conditions. The Purchase Agreement includes typical representations, warranties, and indemnification obligations, as well as restrictions on ownership to prevent any holder from exceeding a 9.99% beneficial ownership threshold.
Q32 Bio funding history
| Date | Round | Amount |
|---|---|---|
| Oct 2020 | Series B | $60.0M |
| Feb 2017 | Venture | $43.6M |
| Jan 2016 | Venture | $23.1M |
Leadership
- Joel Scherer, Founder and Principal Consultant
- Kristin Orr, Senior Director Clinical Operations
- Steven Gillis, Director
- Arthur Tzianabos, Executive Officer, Director
- Richard Gregory, Director
- Kush Parmar, Director
- Ellie Hershberger, Pharm.D., Chief Development Officer
- José Trevejo, M.D., Ph.D., Chief Medical Officer
- Ellie Hershberger, Chief Development Officer
- José Trevejo, Chief Medical Officer
- Adrien Sipos, Chief Medical Officer
- Lee Kalowski, Chief Financial Officer
Verified email and direct lines for Q32 Bio’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
Q32 Bio files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Q32 Bio in the news
- Watkins Advises Homology Medicines in Merger Agreement With Q32 Bio - Latham & Watkins LLP (Dec 27, 2023)
- Homology enters reverse merger with Q32 Bio - BioPharma Dive (Nov 16, 2023)
- Q32 Bio closes Homology merger and $42M private placement - Dealroom (Aug 19, 2026)
- Could Q32 Bio’s ‘Skeleton Key’ Open the Door to New Treatments for an Array of Diseases? - University of Colorado Anschutz (Aug 02, 2024)
- Q32 Bio Announces Closing of Merger with Homology Medicines and Concurrent Private Placement of $42 Million - PR Newswire (Mar 25, 2024)
- Q32 Bio: Bempikibart Keeps The Alopecia Areata Bull Case Alive (NASDAQ:QTTB) - Seeking Alpha (Mar 30, 2026)
Companies similar to Q32 Bio
- AIM ImmunoTech · Biotechnology, Healthcare, Health Care, Therapeutics
- NLS Pharmaceutics Ltd · Biotechnology, Healthcare, Health Care, Therapeutics
- BioLineRx Ltd · Biotechnology, Healthcare, Health Care, Therapeutics
- BioCardia · Biotechnology, Healthcare, Health Care, Therapeutics
- Tempest Therapeutics · Biotechnology, Healthcare, Health Care, Therapeutics
About Q32 Bio: questions and answers
What does Q32 Bio do?
Q32 Bio is a clinical stage biotechnology company whose science targets potent regulators of the adaptive immune system to re-balance immunity and is focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases. Per the National Alopecia Areata Foundation, about 700,000 people in the United States live with alopecia areata, a disease which has a lif
Where is Q32 Bio headquartered?
Q32 Bio is headquartered in CAMBRIDGE.
How many employees does Q32 Bio have?
Q32 Bio has about 34 employees.
Has Q32 Bio raised funding?
Yes. Fundz has recorded 3 funding events for Q32 Bio. The most recent, Series B of $60.0M, was in Oct 2020.
Who leads Q32 Bio?
Joel Scherer is a Founder and Principal Consultant at Q32 Bio.
What is the latest news on Q32 Bio?
On Sep 30, 2026, SEC 8-K (7.01): On September 30, 2026, Q32 Bio Inc. issued a press release regarding the results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata. This announcement was made during a late-breaker session at the European Academy of Dermatology and Venereology Congress 202
Is Q32 Bio a public company?
Yes. Q32 Bio is publicly traded under the ticker QTTB.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy